logo-loader
IXICO PLC

IXICO present PD research at radiology conference

RNS Number : 0803X
IXICO plc
01 October 2026
 

IXICO plc

(“IXICO”, the “Company” or the “Group”)

IXICO to present advancements in neuroimaging for Parkinson’s disease at European radiology conference

 

 

01 October 2026, IXICO plc (AIM: IXI) – London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development and diagnostics in neurological disorders, announces new research the Company presented at the prestigious 42nd European Society for Magnetic Resonance in Medicine & Biology (ESMRMB) 2026 scientific meeting this week.

 

The research compared two magnetic resonance imaging (MRI) approaches for visualising the substantia nigra, a brain region strongly implicated in Parkinson’s disease (PD).  Two MRI techniques sensitive to neuromelanin, a dark pigment found in specific areas of the human brain associated with neurological disease including PD, were studied in healthy volunteers: magnetisation transfer gradient echo (MT-GRE) and turbo spin echo (TSE).

 

Both MRI techniques successfully visualised the substantia nigra, a dark-coloured cluster of neurons located in the midbrain that plays a vital role in controlling movement and coordinating reward pathways. However, the advanced MT-GRE sequence allowed consistently improved contrast between the substantia nigra and surrounding tissue. The findings provide critical insights for the optimisation and more reproducible assessment of neuromelanin using MRI for future PD research and clinical trials. Further research will evaluate the method’s ability to differentiate patient groups and sensitively track disease-related changes over time.

 

IXICO also presented a new method it has developed to measure changes in the substantia nigra without needing to precisely identify and outline the structure first. This offers potential to make the measurement simpler.

 

Robin Wolz, Chief Scientific Officer of IXICO, commented: “Neuromelanin MRI has significant potential as an imaging biomarker in Parkinson’s disease, but its wider use depends on robust and reproducible analysis approaches. Our work presented at ESMRMB shows that both techniques can visualise the substantia nigra, while MT-GRE provides consistently stronger contrast, and also explores an analysis framework for quantitative assessment. These findings are an important step towards optimising neuromelanin MRI for use in future Parkinson’s disease research and clinical trials.”

 

Ends

 

For further information please contact:

 

IXICO plc

+44 (0) 20 3763 7499

Grant Nash, Chief Financial Officer

James Chandler, Chief Business Officer

 

 

Cavendish Capital Markets Limited

(Nominated Adviser and Sole Broker)

 

+44 (0) 20 7220 0500

Giles Balleny, Isaac Hooper (Corporate Finance)

Nigel Birks (Healthcare Specialist Sales)

Harriet Ward (Corporate Broking)

Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com

IXICO is a global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.   As a key part of the global neurological disease research community, the Company has built a global reputation and 20-year track record as an end-to-end Imaging Contract Research Organisation (iCRO) working with leading pharma companies, innovative biotechs, disease consortia and non-profit organisations. IXICO has supported hundreds of neurological clinical trials, analysed hundreds of thousands of scans and built an expansive network of expert imaging centres around the world.  

The IXITM platform is tailor-made for neurological disease, reliably processing data from global trials, precisely measuring key imaging biomarkers associated with the identification, progression and treatment of diseases such as Alzheimer’s, Huntington’s and Parkinson’s.  Image data is interrogated by the platform and IXICO’s expert scientists translating complex data into clinically meaningful while minimizing data variability and increasing reproducibility.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAWPUCPBUPQGRU
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

IXICO CTO on IXI platform upgrade, AI and expanding technology partnerships

IXICO PLC (LSE:IXI, OTC:PHYOF) chief technology officer Mark Austin talked with Proactive's Stephen Gunnion about the latest upgrade to its IXI platform, expanding technology partnerships and the growing role of artificial intelligence (AI) in neurological drug development. Austin explained...

6 hours, 19 minutes ago

4 min read